As a startup in the synthetic blood field, we are entering a rapidly expanding market. The artificial blood substitutes market is forecast to grow significantly, reaching $24.08 billion by 2029. This growth is driven by rising global demand for trauma care solutions, persistent shortages of donor blood, and increased focus on military and emergency healthcare

. Our goal is to position VivoVac at the forefront of this opportunity by advancing HemoGuard-Safe™ to meet critical needs in both civilian and military settings.

Legal Footnote:
“The information contained within this communication and any related links is strictly confidential and intended solely for the recipient to whom access has been provided. Redistribution or sharing of any part of this information, including the links provided herein, to any unauthorized individuals or entities is strictly prohibited without the explicit, written consent of the author. Any unauthorized disclosure, reproduction, or distribution of this information may result in legal action under applicable laws, including but not limited to those of the United States and Australia. By accessing this information, you acknowledge and agree to these confidentiality and legal terms.”